the efficacy of olutasidenib in patients with r/r idh-mutant aml
Published 1 year ago • 187 plays • Length 1:56Download video MP4
Download video MP3
Similar videos
-
1:31
five-year follow-up of olutasidenib for idh1-mutated r/r aml
-
1:17
the efficacy of olutasidenib in aml following venetoclax failure
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:15
outcomes of non-intensive chemotherapy differ for idh1 and idh2-mutated aml
-
3:46
the impact of cytogenetic risk on outcomes of haploidentical transplantation in r/r aml
-
1:06:04
itp: novel treatments
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
8:57
outcomes of sct in t-all and t-lbl
-
0:47
overview of the phase iii enhance trial schema
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
2:00
the development of anti-fibrotic agents for treating myelofibrosis
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
2:14
addressing the high rate of disease relapse following allosct in patients with aml
-
1:13
outcomes following fd & nfd related donor haplo transplantation for patients with acute leukemias
-
1:13
efficacy of transplantation in hl
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
3:21
a phase i trial of hu8f4, an anti-pr1/hla-a2 monoclonal antibody, in r/r myeloid malignancies
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
2:26
assessing the impact of momelotinib on transfusion burden in mf: analysis of simplify-1 & momentum
-
1:03
insights into the cartitude-6 trial: rationale and design
-
1:40
new therapeutic approaches targeting xpo1-overexpression in tp53-mutated myeloid malignancies